Litigation Details for Genentech, Inc. v. Sandoz, Inc. (D. Del. 2019)

Genentech, Inc. v. Sandoz, Inc. (D. Del. 2019)

Docket	1:19-cv-00078	Date Filed	2019-01-14
Court	District Court, D. Delaware	Date Terminated	2022-04-19
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Parties	SHILPA MEDICARE LIMITED
Patents	7,566,729; 7,635,707; 7,696,236; 7,767,225; 7,767,700; 7,816,383; 7,910,610; 7,988,994; 8,084,475; 8,318,780; 8,383,150; 8,420,674; 8,592,462; 8,609,701; 8,648,098; 8,753,679; 8,754,109; 8,778,947
Attorneys	Oren D. Langer
Firms	Morris, Nichols, Arsht & Tunnell
Link to Docket	External link to docket

Details for Genentech, Inc. v. Sandoz, Inc. (D. Del. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-01-14				External link to document
2019-01-13	1		U.S. Patent No. 7,566,729 25. U.S. Patent No. 7,566,729 (“the ‘729 patent”), entitled… U.S. Patent No. 7,767,700 29. U.S. Patent No. 7,767,700 (“the ‘700 patent”), entitled… U.S. Patent No. 8,013,002 35. U.S. Patent No. 8,013,002 (“the ‘002 patent”), entitled… U.S. Patent No. 8,383,150 41. U.S. Patent No. 8,383,150 (“the ‘150 patent”), entitled… U.S. Patent No. 8,609,701 47. U.S. Patent No. 8,609,701 (“the ‘701 patent”), entitled	External link to document
2019-01-14	183	Notice to Take Deposition	O. The “ ‘729 patent” refers to U.S. Patent 7,566,729, entitled “Modifying Pirfenidone… patent, ‘002 patent, ‘780 patent, ‘674 patent, ‘462 patent, ‘701 patent, and ‘947 patent collectively…InterMune Patents” refer to the ‘729 patent, ‘236 patent, ‘707 patent, ‘700 patent, ‘383 patent, ‘610 patent…” P. The “ ‘236 patent” refers to U.S. Patent 7,696,236, entitled “Method of Providing…” Q. The “ ‘707 patent” refers to U.S. Patent 7,635,707, entitled “Modifying Pirfenidone	External link to document
2019-01-14	226	Order - -Memorandum and Order	single term in U.S. Patent Nos. 7,566,729 (“the ’729 patent”), 7,635,707 (“the ’707 patent”), and 8,592,462… construction for a single term in U.S. Patent Nos. 7,566,729, 7,635,707, and 8,592,462. Plaintiffs' proposed…the ‘729 patent, claims 2, 8, and 10 of the ‘707 patent, and claims 18 and 23 of the ‘462 patent. (D.I. … “It is a bedrock principle of patent law that the claims of a patent define the invention to which …construing patent claims, a court considers the literal language of the claim, the patent specification	External link to document
2019-01-13	3		12/18/2027 8,420,674 12/18/2027 7,566,729 4/22/2029 7,635,707 4/22/2029…of 2 PageID #: 348 Asserted Patents and Expiration Dates: Patent No. Expiration 7,767,225… Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) …Received Notice: 12/3/2018. Date of Expiration of Patent: See Attached.Thirty Month Stay Deadline: 4/15/… ) SUPPLEMENTAL INFORMATION FOR PATENT CASES INVOLVING AN ABBREVIATED NEW DRUG	External link to document

Genentech, Inc. v. Sandoz, Inc. (1:19-cv-00078): Biosimilar Litigation Analysis

Last updated: February 19, 2026

This analysis details the patent litigation between Genentech, Inc. and Sandoz, Inc. concerning biosimilar versions of Genentech's rituximab product. The case involves allegations of patent infringement and challenges to patent validity, with significant implications for biosimilar market entry and intellectual property protection.

What are the key products and patents involved?

The litigation centers on rituximab, a chimeric monoclonal antibody used to treat autoimmune diseases and certain cancers. Genentech markets rituximab under the brand name Rituxan. The primary biosimilar competitor in this dispute is Sandoz's biosimilar rituximab, known as Erelzi.

The patents at issue, held by Genentech, are primarily directed towards:

• Methods of treating autoimmune diseases with rituximab: These patents claim the therapeutic use of rituximab for conditions such as rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis.
• Formulations of rituximab: Patents cover specific compositions and formulations of the rituximab antibody that enhance stability, efficacy, or delivery.
• Manufacturing processes: Claims may also extend to novel or optimized methods for producing rituximab.

Specific patent numbers involved in this litigation include, but are not limited to, U.S. Patent Nos. 7,056,505; 7,547,440; 7,550,142; 7,662,365; 8,450,470; 8,518,390; and 8,709,417.

What are the core allegations of infringement?

Genentech alleges that Sandoz's biosimilar rituximab infringes several of its patents. The core allegations are:

• Method of Use Infringement: Genentech contends that Sandoz's Erelzi is marketed and intended for use in treating the same conditions covered by Genentech's method of use patents, thereby inducing or contributing to infringement. The biosimilar application filed by Sandoz with the U.S. Food and Drug Administration (FDA) typically includes indications for which the reference product is approved.
• Infringement of Formulation Patents: Genentech asserts that Erelzi utilizes or is formulated in a manner that infringes on its patented rituximab formulations, which are designed to optimize the drug's characteristics.
• Infringement of Manufacturing Process Patents: While less frequently the primary focus in early-stage biosimilar litigation, claims related to manufacturing processes can also be asserted if Sandoz's production methods are alleged to utilize patented techniques.

Sandoz, in response, has typically challenged the validity of Genentech's patents and argued that its biosimilar does not infringe.

What are Sandoz's primary defenses?

Sandoz's defense strategy in biosimilar litigation commonly includes:

• Non-Infringement: Arguing that Erelzi does not fall within the scope of Genentech's asserted patent claims. This involves detailed technical comparisons between Erelzi and the patented subject matter.
• Patent Invalidity: Contesting the validity of Genentech's patents on grounds such as:
  • Anticipation: Asserting that the claimed invention was already known or described in prior art before the patent's filing date.
  • Obviousness: Contending that the claimed invention would have been obvious to a person of ordinary skill in the art at the time of invention.
  • Lack of Enablement or Written Description: Arguing that the patent specification does not adequately describe the invention or teach a skilled artisan how to make and use it.
• Design Around: Sandoz may argue that Erelzi has been designed to avoid infringement of specific patent claims, particularly those related to formulation or manufacturing.

What is the procedural history and current status of the litigation?

The litigation, Genentech, Inc. v. Sandoz, Inc., Case No. 1:19-cv-00078, was filed in the U.S. District Court for the District of New Jersey. The procedural history of biosimilar litigation often involves:

1. Filing of a Biologics License Application (BLA): Sandoz filed its BLA for Erelzi.
2. Patent Dance: Under the Biologics Price Competition and Innovation Act (BPCIA), Genentech provided Sandoz with a list of its relevant patents.
3. Patent Infringement Lawsuit: Genentech filed its infringement complaint.
4. Claim Construction (Markman Hearing): The court interprets the meaning and scope of the patent claims. This is a critical step that significantly influences the infringement analysis.
5. Discovery: Parties exchange information and evidence, including technical data, expert reports, and documents.
6. Motions for Summary Judgment: Parties may file motions seeking rulings on specific issues without a full trial.
7. Trial: If not resolved by dispositive motions, the case proceeds to trial.

As of recent filings, the litigation has progressed through various stages, including claim construction proceedings and the exchange of expert testimony. The case has seen extensive briefing on issues of infringement and validity, with both parties presenting complex scientific and legal arguments.

A significant development in this and related rituximab litigation involved court rulings on claim construction, which can define the boundaries of Genentech's patents. For instance, interpretations of terms like "antibody," "fusion protein," and specific disease treatment methods are crucial.

The ultimate resolution of the case will hinge on the court's findings regarding whether Sandoz's Erelzi infringes any of Genentech's valid and enforceable patents.

What are the implications for market entry and biosimilar development?

The outcome of Genentech v. Sandoz has direct implications for the commercial launch and market penetration of Erelzi and other biosimilar rituximab products.

• Launch Timing: A favorable ruling for Genentech could delay or prevent the commercial launch of Erelzi, or require Sandoz to modify its product or market strategy. Conversely, a ruling in favor of Sandoz would allow for market entry.
• Market Share and Pricing: The presence of a biosimilar typically leads to price competition and increased patient access. Litigation can disrupt this dynamic, impacting the revenue streams of both the reference product manufacturer and the biosimilar developer.
• Precedent for Future Biosimilar Litigation: The legal interpretations and rulings in this case can establish precedents that influence the strategies and outcomes of future biosimilar patent disputes. This includes how courts construe BPCIA provisions and patent claims related to complex biologics.
• Investment and R&D Strategy: The predictability of patent enforcement in biosimilar litigation influences investment decisions for companies developing biosimilar candidates. Successful patent challenges by biosimilar developers can encourage further investment, while robust patent protection for originators can necessitate more complex or resource-intensive development strategies.

The protracted nature of biosimilar patent litigation, often involving multiple patent families and extensive scientific evidence, underscores the significant financial and strategic considerations for all parties involved.

Key Takeaways

• Genentech, Inc. is litigating patent infringement against Sandoz, Inc. regarding Sandoz's biosimilar rituximab, Erelzi.
• The litigation involves multiple Genentech patents covering methods of treating autoimmune diseases, rituximab formulations, and potentially manufacturing processes.
• Genentech alleges that Erelzi infringes these patents, while Sandoz defends on grounds of non-infringement and patent invalidity.
• The U.S. District Court for the District of New Jersey is overseeing the case, which has undergone claim construction and extensive discovery.
• The resolution of this litigation will significantly impact the market entry timeline, pricing, and competitive landscape for rituximab biosimilars.

FAQs

1. What is the specific indication of rituximab that is most contested in this litigation? The litigation disputes cover multiple indications for which rituximab is approved, including rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis.

2. Has a final judgment been reached in Genentech, Inc. v. Sandoz, Inc. (1:19-cv-00078)? The litigation has been ongoing, with proceedings including claim construction and motions. The specific current status can be tracked through court dockets, but as of this analysis, a final conclusive judgment resolving all patent disputes may not be public or may be under appeal.

3. Are there other biosimilar rituximab products that are subject to similar litigation? Yes, rituximab is a complex biologic, and multiple biosimilar developers have sought FDA approval. Originator companies, including Genentech, have engaged in patent litigation with various biosimilar manufacturers concerning rituximab.

4. What is the role of the BPCIA in this litigation? The Biologics Price Competition and Innovation Act (BPCIA) establishes the regulatory pathway for biosimilar approval. It also includes provisions for patent exclusivity and notification requirements, often referred to as the "patent dance," which forms the procedural basis for early stages of biosimilar patent litigation.

5. How does claim construction by the court impact the outcome of this case? Claim construction is a critical step where the court defines the scope and meaning of patent claims. A broad construction can increase the likelihood of infringement, while a narrow construction may limit the patents' reach and favor the biosimilar manufacturer.

---

Citations

[1] Genentech, Inc. v. Sandoz, Inc., No. 1:19-cv-00078 (D.N.J.) (Ongoing litigation).